Christian cachola oldham
1 / 7

Christian Cachola-Oldham - PowerPoint PPT Presentation

  • Uploaded on

Christian Cachola-Oldham. American DG Energy DANAHER CP Oncothyreon Inc. American DG Energy.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' Christian Cachola-Oldham' - kasimir-hodge

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Christian cachola oldham

Christian Cachola-Oldham

American DG Energy


Oncothyreon Inc.

American dg energy
American DG Energy

  • American DG Energy, Inc. distributes and operates on-site energy systems that produce electricity, hot water, heat, and cooling. It offers cogeneration systems that produce electricity from an internal combustion engine and water chiller systems for building cooling applications. As of December 31, 2007, American DG Energy had installed energy systems, representing approximately 3,645 kilowatts and 29.2 million British thermal units of heat and hot water, as well as 600 tons of cooling. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.

American dg energy1
American DG Energy

Ticker: ADGE.OB

Last trade 3.25

EPS (ttm):-0.07

P/E (ttm): N/A


Danaher cp

  • Danaher Corporation, together with its subsidiaries, designs, manufactures, and markets professional, medical, industrial, commercial, and consumer products, primarily in the United States, Europe, and Asia. It operates in four segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools and Components. The Professional Instrumentation segment offers analytical instruments and related consumables that detect and measure chemical, physical, and microbiological parameters in drinking water, wastewater, groundwater, ocean bodies, and ultrapure water; ultraviolet disinfection systems; and chemical treatment solutions and analytical services to address corrosion, scaling, and biological growth problems in boiler, cooling water, and industrial waste water applications. This segment also provides environmental monitoring and leak detection systems; vapor recovery equipment; fuel dispensers; point-of-sale and merchandising systems; submersible turbine pumps; and remote monitoring and outsourced fuel management services. The Medical Technologies segment manufactures dental products, acute care, pathology diagnostics, and life sciences instrumentation for research and clinical medical professionals. The Industrial Technologies segment offers product identification; precision motion control equipment; aircraft and defense equipment; and sensors and controls that measure and control discrete manufacturing variables, such as temperature, position, quantity, level, flow, and time. The Tools and Components segment produces mechanics’ hand tools, including ratchets, sockets, and wrenches, as well as specialized automotive service tools for the professional and ‘do-it-yourself’ markets. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, District of Columbia.

Danaher cp1

Ticker: DHR

Last Trade 52.93

EPS (ttm):3.95

P/E (ttm):14.31


Oncothyreon inc
Oncothyreon Inc

  • Oncothyreon, Inc., a biotechnology company, together with its subsidiaries, focuses on the development and commercialization of therapeutic products for the treatment of cancer. The company’s lead product candidate includes Stimuvax, a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Its pipeline of clinical and pre-clinical stage proprietary small molecule product candidates comprises PX-12, PX-478, and PX-866. PX-12 is in Phase II development for pancreatic cancer. PX-478, a Phase 1 trial product, is a small molecule inhibitor of hypoxia inducible factor-1a (HIF-1a) for advanced metastatic cancer. PX-866 is an inhibitor of the phosphatidylinositol-3-kinase /PTEN/Akt pathway indicated for advanced solid tumors and glioma. In addition, Oncothyreon offers BGLP40 Liposome Vaccine, a preclinical stage liposomal glycolipopeptide cancer vaccine for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, and prostate, as well as various types of lung cancer. The company has strategic collaboration with Merck KGaA, under which Merck KGaA has assumed worldwide responsibility for the clinical development and marketing of Stimuvax. Oncothyreon, Inc. was founded in 1985 and is headquartered in Bellevue, Washington.

Oncothyreon inc1
Oncothyreon Inc

  • Ticker: ONTY

  • Last Trade:2.80

  • EPS (ttm):0.36

  • P/E (ttm):7.69

  • Beta:1.61